RN
Cartesian Therapeutics, Inc.
RNAC · NASDAQ
$8.19 -7.35% (-$0.65)
1M -6.08%
Market Cap $247.7M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 167.70x
P/FCF N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 70.66%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak FCF margin 5,291.54%
Op. margin 6,679.69%
Gross margin 766.42%
Quality
0 /100
Poor ROA 48.31%
Asset turnover 0.00x
ROIC 30.78%
Debt
43 /100
Moderate Int. coverage -188.07x
Current ratio 7.48x
Net debt/EBITDA N/A
Stability
26 /100
Unstable Profitable years 0
EPS volatility 1,029.74%
Beta 0.62x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RNAC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carsten Brunn
Employees
75
Headquarters
Frederick
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report